Recombinant B-type Natriuretic Peptide Nesiritide Attenuates Vascular Remodelling by Reducing Plasma Aldosterone in Rabbits

Heart Lung and Circulation

Volumn 21, Issue 9, 2012, Pages 551-555

  Liu, Shu Qin ^a   Xie, Hong Wen ^a   Yan, Huang Ying ^a   Lu, Yu Qiao ^a   Wang, Le Xin ^a,b  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Aldosterone; Nesiritide; Rabbits; Vascular remodelling

Indexed keywords

ALDOSTERONE; BRAIN NATRIURETIC PEPTIDE; NESIRITIDE;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTICLE; BALLOON CATHETER; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENDOTHELIUM INJURY; ILIAC ARTERY; ILIAC ARTERY OBSTRUCTION; LIPID STORAGE; MALE; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOIMMUNOASSAY; VASCULAR DISEASE;

ALDOSTERONE; ANIMALS; CONSTRICTION, PATHOLOGIC; ILIAC ARTERY; MALE; NATRIURETIC PEPTIDE, BRAIN; RABBITS; RECOMBINANT PROTEINS;

EID: 84864324522     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2012.04.013     Document Type: Article

References (20)

1. Mills R.M., Lejemtel T.H., Horton D.P., Liang C., Lang R., Silver M.A., et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo controlled clinical trial. J Am Coll Cardiol 1999, 34:155-162.
2. Colucci W.S., Elkayam U., Horton D.P., Abraham W.T., Bourge R.C., Johnson A.D., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000, 343:246-253.
3. The VMAC Investigators Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531-1540.
4. Hillock R.J., Frampton C.M., Yandle T.G., Troughton R.W., Lainchbury J.G., Richards A.M. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 2008, 94:617-622.
5. Zhao Q., We T.G., Li Y., Li B., Luo J.Y., Wang L.X. Low dose nesiritide improves renal function in heart failure patients following acute myocardial infarction. Heart Vessel 2010, 25:97-103.
6. O'Connor C.M., Starling R.C., Hernandez A.F., Armstrong P.W., Dickstein K., Hasselblad V., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011, 365:32-43.
7. Chen H.H., Martin F.L., Gibbons R.J., Schirger J.A., Wright R.S., Schears R.M., et al. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart 2009, 95:1315-1319.
8. Dickey D.M., Flora D.R., Bryan P.M., Xu X., Chen Y., Potter L.R. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 2007, 148:3518-3522.
9. Liu S.Q., Yu Y.Y., Xie H.W., Yu K., Wang L.X. Treatment with nesiritide, a recombinant B-type natriuretic peptide, reduces vascular remodeling following balloon-induced endothelial injuries in rabbits. Tohoku J Exp Med 2010, 222:219-223.
10. Sica D., Oren R.M., Gottwald M.D., Mills R.M. Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction. Clin Cardiol 2010, 33:330-336. Scios 351 Investigators.
11. Keidar S., Kaplan M., Pavlotzky E., Coleman R., Hayek T., Hamoud S., et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213-2220.
12. Amano T., Matsubara T., Izawa H., Torigoe M., Yoshida T., Hamaguchi Y., et al. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol 2006, 97:785-788.
13. Ivanes F., Susen S., Mouquet F., Pigny P., Cuilleret F., Sautière K., et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J 2012, 33:191-202.
14. Edelmann F., Tomaschitz A., Wachte R., Gelbrich G., Knoke M., Düngen H.-D., et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J 2012, 33:203-212.
15. Kivela A., Hartikainen J. Restenosis related to percutaneous coronary intervention has been solved?. Ann Med 2006, 38:173-187.
16. Kennedy K.L., Lucas A.R., Wan W. Local delivery of therapeutics for percutaneous coronary intervention. Curr Drug Deliv 2011, 8:534-556.
17. Han B., Ghanim D., Peleg A., Uretzky G., Hasin Y. Loss of systemic endothelial function post-PCI. Acute Card Care 2008, 10:79-87.
18. Yancy C.W., Saltzberg M.T., Berkowitz R.L., Bertolet B., Vijayaraghavan K., Burnham K., et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I Trial). Am J Cardiol 2004, 94:595-601.
19. Yoshimura M., Yasue H., Ogawa H. Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can J Physiol Pharmacol 2001, 79:730-735.
20. Villereal D., Freeman R.H., Ream G. Natriuretic peptides and salt sensitivity: endocrine cardiorenal integration in heart failure. Congest Heart Fail 2002, 8:29-36.